Assembly Biosciences, Inc. (ASMB) vs Editas Medicine, Inc. (EDIT)

A side-by-side comparison of Assembly Biosciences, Inc. and Editas Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ASMB vs EDIT

growth of $100 · dividends reinvested · last 10y
ASMB -76.4% (-13.4%/yr)EDIT -81.4% (-15.5%/yr)ASMB compounded faster over this window
0200400600800Start $10020182020202220242026$24$19
ASMB EDIT

ASMB vs EDIT: by the numbers

  • •ASMB is the larger company ($436M vs $423M market cap).
  • •Both run net losses; ASMB's is the smaller (-0.06% vs -157.32% net margin).
  • •Both shrank revenue over the past five years; ASMB's decline was smaller (-1.78% vs -10.34% CAGR).

Metrics side by side

Valuation

MetricASMBEDIT
P/E ratio40.04N/A
P/S ratio5.838.99
P/B ratio1.434.02

Profitability

MetricASMBEDIT
Gross margin99.82%100.00%
Operating margin-11.75%-245.15%
Net margin-0.06%-157.32%
ROE-0.01%-70.24%
ROIC-2.86%-48.61%

Growth (annualized)

MetricASMBEDIT
Revenue CAGR (5Y)-1.78%-10.34%
Total return CAGR (5Y)-10.66%-40.76%

Frequently asked

Which has grown faster, ASMB or EDIT?
Neither grew: over the past five years both shrank revenue, with ASMB's decline the smaller — ASMB at a -1.78% CAGR versus EDIT at -10.34%.
How have ASMB and EDIT total returns compared?
Over the past 10 years, ASMB delivered -13.41% and EDIT delivered -15.75% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.